Highlights from Day 1 of SABCS 2024 by Sara Tolaney

The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to 13th, 2024 at the Henry B. Gonzalez Convention Center in San Antonio, TX, USA.

SABCS is expected to attract around 10,000+ attendees from more than 102 countries, including oncologists, researchers, and healthcare professionals.

This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancerand premalignant breast disease to an international audience of academic and private physicians and researchers.

Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches.

Her work has demonstrated that a relatively low risk regimen is beneficial in women with early stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines. She has developed several follow-up studies looking at novel approaches to early stage HER2-positive disease and has also played a significant role in development of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy in breast cancer.

Sara Tolaney shared her insights from DAY 1 of SABCS 2024:

PADMA study:

“PADMA study: ET + palbo vs chemo (cape/taxane/navelbine) in high risk HR+ MBC–> confirms ET+ cdk4/6i is 1L SOC

n=150
42% with liver mets
6%BRCAm
TTF: 17.2 vs 6.1mo HR 0.46
PFS: 18.7 vs 7.8 mo, HR 0.45
OS trend: 46.1 vs 36.8 month”

MARGOT Study:

“MARGOT study: Preop THP vs TMP (M= margetuximab) in patients with a CD16AF alleleNo significant improvement in pCR with TMP c/w THP

n=171, pCR: 56% vs 46%, p=0.25
HR+ pCR 54% vs 35%, HR-: 60% vs 71%

Presented by the superstar Ada Waks.”

OlimpiA update presented by Judy Garber:

“OlympiA update, median follow up 6.1 yrs presented by Judy Garber.

iDFS: TNBC: HR 0.65, HR 0.68
OS ITT: 0.72

Fewer new primary cancers seen in olaparib arm; no evidence of increased risk of MDS or AML.”

Analysis of risk-reducing surgeries:

“Analysis of risk-reducing surgeries + OS in patients with BRCAm with h/o breast cancer dx’d <40 yo

n=5290 (63.5% BRCA1)

RRM n=2910 (55%), f/u 5.1 years, OS : 0.65, DFS 0.58

RRSO n=2782 (53%), median age 39.7, OS 0.58; greater effect in BRCA1.”

PRO-B Trial:

“PRO-B trial

pts with mBC randomized to intervention group (n=463) with PRO web tool vs standard of care (n=461)

Primary endpt: Reduction in fatigue in intervention group significant at 6 mo, seen across all subgroups.”

Aleix Prat on 1L treatment approaches in HER2+ BReady Cancer:

“Excellent discussion by Aleix Prat on 1L treatment approaches in HER2+ BC and if there is a role of ADCs in preop HER2+ dz

More work ongoing for ADCs in 1L mHER2+ BC(DB09) and for preop HER2 + disease (DB11).”

EMBER-3 Study:

“EMBER-3

Imulen+ abema vs Imlun vs SOC ET

Imlun superior to SOC ET in ESR1m, not in ITT
Imlun + abema vs Imlun, PFS 9.4 vs 5.5 mo, HR 0.57, p<0.0001 (better in ESR1m + w/o ESR1m)
(65% prior cdk4/6i).”

VALENTINE:

“VALENTINE: Preop HER3DXd in ER+ BC
Ki67≥20% or high genomic assay
HER3DXd +/- letrozole vs A(or E) -CT
n=120

pCR: 4% vs 2.1% vs 4.2%.”

DESTINY-Breast06:

“DESTINY-Breast06: Efficacy by pace of disease progression

PFS with TDXd regardless of time to progression on 1L ET+cdk 4/6i
PFS2 prolonged with TDXd combination with chemotherapy (20.3 vs 14.7mo)
TDXd with benefit regardless of disease burden.”

KN522 Biomarkers by Joyce O’Shaughnessy:

“KN522 Biomarkers by Joyce O’Shaughnessy

Tcellinfl GEP prognostic
TMB assoc with higher EFS with pembro
PTENloss assoc with pCR + EFS
HRD correlated with pCR but not EFS
TNBC molecular subtypes: LAR lowest pCR with chemo and largest improvement with pembro.”

Further Reading:

The San Antonio Breast Cancer Symposium (SABCS) 2024

SABCS’s Social Media Ambassadors 2024